AXM Pharma Completes Acquisition of Controlling Interest in Chinese Pharmaceutical Distributor
2006年7月6日 - 9:41PM
ビジネスワイヤ(英語)
AXM Pharma, Inc. (OTC: AXMP), a manufacturer of proprietary and
generic pharmaceutical and nutraceutical products for the Chinese
and other Asian markets, announced today that it has completed the
acquisition of a 51% interest in Liaoning Ming Cheng Medical &
Pharmaceutical Co., Ltd. ("Ming Cheng") through the issuance of 3.7
million shares of AXM Pharma's common stock. Founded in 2000, Ming
Cheng is a distributor of pharmaceutical and other medical products
in China. The acquisition closed on July 1, 2006. AXM will
consolidate the results of Ming Cheng for financial reporting
purposes beginning in the Company's third quarter. Founded in 2002,
Ming Cheng is located in Shenyang, a key pharmaceutical
distribution center in northeastern China, and is mainly engaged in
the distribution of patented Chinese Medicines, antibiotics,
biochemical medicines and healthcare products. Ming Cheng's sales
are primarily in Beijing, Tianjin and the provinces of Hebei,
Liaoning, Jilin and Heilongjiang. Ming Cheng distributes over 5,000
products and has exclusive distribution rights to approximately 100
products. The company has approximately 100 employees and sells to
approximately 13,000 wholesalers and retail outlets. "We are
pleased that we were able to complete the acquisition of a majority
interest in Ming Cheng," said Wang Weishi, CEO of AXM Pharma. "Ming
Cheng's large customer will allow us to market our innovative
pharmaceutical products to an expanded customer base. In addition,
its broad range of innovative products, including many proprietary
products, will allow us to penetrate new markets and further expand
the customer base. We believe this transaction should enable the
company to significantly increase revenue during the second half of
the year, and improve its operating results." About AXM Pharma,
Inc. AXM Pharma, Inc., through its wholly owned subsidiary, AXM
Pharma Shenyang, Inc. ("AXM Shenyang"), is a manufacturer of
proprietary and generic pharmaceutical products, which include
injectables, capsules, tablets, liquids and medicated skin products
for export and domestic Chinese sales. AXM Shenyang is located in
the City of Shenyang, in the Province of Liaoning, China. AXM
Shenyang has an operating history of approximately 10 years. For
additional information on AXM Pharma Inc., please visit
http://www.axmpharma.com Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: The statements contained
in this news release include certain predictions and projections
that may be considered forward-looking statements under securities
law, including the statements regarding the Company's opportunities
for future growth. These statements involve a number of important
risks and uncertainties that could cause actual results to differ
materially including, but not limited to, the performance of joint
venture partners, obtaining regulatory approvals to market the
Company's products, the uncertainties associated with distributing
products in a developing country such as China, the availability of
cash to meet near term requirements as well as other economic,
competitive and technological factors involving the Company's
operations, markets, services, products and prices. With respect to
AXM, except for the historical information contained herein, the
matters discussed in this news release are forward-looking
statements involving risks and uncertainties that could cause
actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, AXM's extremely limited operating
history, uncertainties related to the Company's access to
additional capital, competition and dependence on key management.
AXM Pharma (CE) (USOTC:AXMP)
過去 株価チャート
から 11 2024 まで 12 2024
AXM Pharma (CE) (USOTC:AXMP)
過去 株価チャート
から 12 2023 まで 12 2024